-0.450 (-6.50%)
Range 6.435 - 6.910   (7.38%)
Open 6.810
Previous Close 6.920
Buy Price 6.500
Buy Volume 9
Sell Price 6.510
Sell Volume 9
Volume 629,285
Value -
Measurement Type Value
EPS (USD) -0.132
Trailing EPS (USD) 0.297
NAV (USD) 6.997
Cash In Hand (USD) 10.104
Dividend -
Dividend Yield (%) -
PE -
Trailing PE 23.135
Price / NAV 0.983
Price / Cash In Hand 0.681
Issued & Paid-up Shares 83,102,700
Treasury Shares -
Market Cap (M) 571.747
Par Value (USD) n.a.
Beta - 75 Days 0.253
R-Squared - 75 Days(%) 0.1
Beta - 500 Days -15.239
R-Squared - 500 Days(%) 1.03
Under CPF Investment Scheme (CPFIS) No
Index Components
Delayed prices. Updated at 22 Jan 2022 04:17.
Data powered by

Upcoming Events

* Stock event date based on US timezone.


Release Date 24 Mar 2022
View All Events


Aviragen Therapeutics, Inc., formerly Biota Pharmaceuticals Inc., is a biopharmaceutical company. The Company is focused on the discovery and development of direct-acting antivirals to treat infections. It has approximately four product candidates in clinical development that address viral infections that have limited therapeutic options. Its product candidates include vapendavir, which is an oral treatment for human rhinovirus (HRV) infections in moderate-to-severe asthmatics that is being evaluated in its Phase IIb SPIRITUS trial; BTA074, a Phase II topical antiviral treatment for genital warts caused by human papillomavirus (HPV) types 6 and 11; BTA585, an oral fusion (F) protein inhibitor in Phase IIa development for the treatment and prevention of respiratory syncytial virus (RSV)-A and RSV-B infections, and laninamivir octanoate in Phase II development for the treatment of influenza A and B infections. It also has preclinical RSV non-fusion inhibitor program.

There are 1 follower